GNRH1 and COVID-19: For instance, in the Hormonal Intervention for the Treatment in Veterans with COVID-19 Requiring Hospitalization (HITCH) trial (NCT04397718) which tested degarelix, a gonadotropin-releasing hormone (GnRH) antagonist that rapidly suppresses testosterone levels, in male veterans hospitalized with COVID-19, no improvement in clinical outcome was observed compared to placebo (39).